to fully appreciate the variability of results according to location and be able to apply the evaluation to their own setting.
Of the 18 articles included in the review, only three explicitly stated the decision-making audience. It was not possible to infer a decision-making audience in eight studies. The target population was well reported, as were resource and cost data, and clinical data used for estimates of relative risk reduction. However, baseline risk was rarely adapted to the relevant jurisdiction, and when no decision maker was explicit it was difficult to assess whether the reported cost and resource use data were in fact relevant. A few studies used sensitivity analysis to explore elements of generalisability, such as compliance rates and baseline fracture risk rates, although such analyses were generally restricted to evaluating parameter uncertainty.
This review found that variability in cost effectiveness across locations is addressed to a varying extent in modelling studies in the field of osteoporosis, limiting their use for decision makers across different locations. Transparency of reporting is expected to increase as methodology develops and decision makers publish 'reference case' type guidance.
Healthcare systems are increasingly under finan-ed trial that was undertaken in one jurisdiction (e.g. cial pressure to optimise the use and allocation of the country or province) relevant to another. Secondly, available resources. To support decision making geographical variability can generally be dealt with many countries have now introduced some formal in published modelling studies, since the general assessment process to evaluate whether health tech-purpose of models is to identify optimal solutions to nologies represent good 'value for money'. [1] Deci-specific decision problems faced by particular decision-analytic modelling is widely used in health sion makers in their own jurisdiction. For example, technology assessment to evaluate the effectiveness the National Institute for Health and Clinical Exceland cost effectiveness of alternative options under lence's (NICE) technology appraisal process often conditions of uncertainty. [2, 3] This form of model-includes decision models submitted by manufacturling is necessary in situations where a single primary ers and/or developed by the academic Technology source of data (e.g. a randomised trial) does not Assessment Team (see www.nice.org.uk). In each wholly satisfy the data needs of a decision problem, case, the decision maker (i.e. the NICE Appraisal and additional data sources and assumptions are Committee) and the jurisdiction (i.e. NHS) are exneeded. These situations include synthesising infor-plicit. An important feature of economic models is mation when a number of estimates of a particular that they relate to the policy-maker(s) and jurisdicparameter exist, extending the results of a short-term tion(s) whose decision the model is designed to trial over a long-term time horizon, increasing the inform. In published journal articles these are not range of alternative treatment strategies being com-always explicitly stated, in spite of such information pared and adapting the results of a study undertaken being paramount to an assessment of the generalin one jurisdiction to be relevant to another. [4] It is isability of study results to other decision makers. the last example that this paper is concerned with.
Therefore, it is of value to review published modelThe use of decision models to explore issues of ling studies to assess how clearly the authors have variability and generalisability in cost effectiveness identified the decision-making audience of their between jurisdictions is of interest for two reasons. work, the extent to which the data incorporated into Firstly, models are often used to make the results of these models are the most appropriate for that decia particular patient-level study, such as a randomis-sion maker and the degree to which they have as-sessed the importance of any variability between 1. Method of Review locations (e.g. regions) within a particular jurisdiction (e.g. country).
Aims and Objectives
In recent years, significant contributions in the The aim of the review was to assess how pubarea of generalisability have been published, much lished model-based economic evaluations in the of which are in the statistical area of cost-effective-field of osteoporosis deal with variability in results ness analysis. [5] [6] [7] [8] [9] [10] [11] [12] [13] There has been little evidence in between jurisdiction-specific decision problems. the area of conceptual analysis and this article at-
The review set out to address the following spetempts to fill this gap. Rather than select a sample of cific objectives for each economic evaluation: model-based studies across a range of diseases and 1. to assess whether the decision-making audience interventions, the particular clinical area of osteo-was clearly defined; porosis has been selected for the review for two 2. to establish whether the model was transparently reasons. Firstly, a large number of cost-effective-reported in terms of study question, structure and ness models are available, since the majority of data inputs; 3. to assess the relevance of the data inputs used in cost-effectiveness studies in osteoporosis are the model to the stated decision maker or jurisdicmodel-based. In a review of economic evaluations tion; in this field undertaken in 1998, 16 studies were 4. to assess how fully the robustness of the model's identified, all of which were based on deciresults to variation in data inputs between jurisdicsion-analytic models. [14] Secondly, there is likely to tions was assessed. be pronounced variability between jurisdictions (e.g. countries, provinces) in many of the parameters
Inclusion and Exclusion Criteria
going into these models. This variability potentially
The inclusion criteria were full economic evaluarelates to baseline event rates, resource use, cost and tion models evaluating therapeutic interventions in utility. [15] osteoporosis. Only studies reporting a summary Osteoporosis is characterised by low bone minermeasure of cost effectiveness (e.g. cost-effectiveal density (BMD) and deterioration of bone tissue, ness ratio) were included in the review, as these leading to enhanced bone fragility and consequent studies combine an estimate of both costs and effecincrease in fracture risk. The disease is manifested in tiveness and present an overall assessment of the terms of a high occurrence of hip, wrist and verte-value for money of the alternative interventions of bral fractures, and is most prominent in post-interest to decision makers. Since this was a review menopausal women. Development of fractures is a where methodology rather than results was of pricomplex function of osteoporosis, age and other risk mary interest, only studies published in English factors which evolve over time. The majority of were included. Economic evaluations that did not trials in this area have evaluated the impact of osteo-describe the structure and assumptions underlying a porosis treatments on the intermediate endpoint of model were excluded from the assessment, as were simple cost analyses, secondary reviews of econom-BMD. [16] Historically, there has been a scarcity of ic evaluation models and studies that did not present literature evaluating final endpoints. [17] The need to a summary measure of cost effectiveness. estimate links between intermediate endpoints and ultimate measures of health gain, together with the funded project on generalisability that commenced at that time. [15] A search strategy was devised to decision maker, it was possible to infer a decision retrieve published papers reporting economic evalu-maker from the perspective taken and the data incoration models of interventions for osteoporosis. The porated. In addition, the studies were assessed acsearches were conducted using the following biblio-cording to whether the study question was clearly graphic databases: MEDLINE, EMBASE, Econlit, stated or not, or whether the study question could be Health Economic Evaluation Database (HEED), the easily inferred. internal catalogue of the NHS CRD/CHE informa-
Transparent Reporting of Model Specification
tion service, the Health Technology Assessment Transparent reporting of a model is a prerequisite (HTA) Database and the administration version of to understanding the relevance of the model to the the NHS Economic Evaluation Database (NHS target decision maker, as well as to assessing its EED) held at the NHS CRD. The databases were generalisability to other decision makers and jurissearched from 1980 until 2001, or from the earliest dictions. The specification of study setting (e.g. publication in the relevant database after that date, country, and primary or secondary care) and patient and searches were restricted to English language population were therefore assessed. In addition, the documents. All the references from the database description and justification of alternative intervensearches were imported into an Endnote Library and tions was considered, and an assessment of transparde-duplicated. The search strategies are detailed ent reporting of the model structure and key assumpelsewhere. [15] Searches were extended to bibliogra-tions was made. phies of retrieved articles, and reference lists of key The ease with which model inputs can be traced, and assessed according to the inclusion criteria. and the relevance of those inputs to the stated decision maker, will influence the degree to which a
Review Process
model is considered applicable in the target setting. A data extraction tool was developed specifically The reporting of sources and the relevance of key for the purpose of this review. For included studies, data inputs to the model were therefore assessed, information relevant to the review was extracted ranging from clinical data and their valuation to into a data extraction form by one of the authors (H. resource use and unit costs. Models that reported Urdahl). The information was summarised in data and referenced both baseline risks and risk reductables, which provided the basis for assessment of tions were considered as having provided sources of the studies. Key characteristics of the models clinical data, whereas models that only reported presented in each publication were recorded, as was references for risk reduction were assessed as havinformation on interventions studied and results of ing partially provided sources of clinical data. the evaluations. The four numbered sections of the The use of sensitivity analysis to explore the robustness of model results to variation in data in- puts that may exist within and between jurisdictions Being aware of the target decision-making audi-was assessed. It has been argued [15] that resource use ence for a model is important to a judgement about estimates and their valuation, as well as health state the appropriateness of the model and its inputs, and estimates and their valuation, may vary across setthe review attempted to elicit the target decision-tings. This variation may exist between units within making audience or jurisdiction. In some instances, a given decision maker's jurisdiction, [15] and to prowhere models did not explicitly state the target vide information to the decision maker, the implica-tions of such variation should be assessed. The ies covered the following countries: Australia, Caauthors may also choose to assess the robustness of nada, Denmark, UK, US and Italy. Apart from the their model's results to the level of variation that Italian study, [29] all results were presented in local might be expected between jurisdictions. For exam-currencies. Many models based the evaluation on a ple, the average length of stay in hospital for patients time horizon spanning the lifetime from the onset of with a hip fracture has been reported to be 29.6 days treatment at menopause, usually assumed to be 45 or in Aberdeen and 41.7 days in Peterborough, [18] 50 years of age. [17, 19, 24, 25, [30] [31] [32] [33] [34] [35] Others evaluated a whereas the national average in Denmark has been more limited time horizon, for example 2 years in reported to be 21 days. [19] Francis et al., [26] 3 years in Rosner et al., [36] 3-4 years in Torgerson and Kanis [28] and 1 year in VisenSimilarly, the estimate of clinical effect incorpotin et al. [29] rated into a model may depend on the study population and target population of the model. The robustOverall, the main base-case results of the studies ness of the model's results under a range of clinical did not reveal any systematic differences across the effectiveness estimates from different studies could, studies that might be explained by location (table I) . therefore, be explored in sensitivity analysis. Mod-Neither systematic variation in cost-effectiveness els may also undertake adjustments to translate the estimates within countries nor systematic changes results of explanatory trials that may not hold in over time were apparent from the review. Despite routine clinical practice. For example, compliance is focusing on the osteoporosis area, the models comgenerally acknowledged to be higher within the pared a range of interventions and presented results context of randomised trials than in clinical practice, using a variety of outcomes. For example, Ankjaerand this may contribute substantially to the reduc-Jensen and Johnell [19] reported average cost per hip tion in efficacy when an intervention is used in a fracture avoided in screened and unscreened populanon-trial environment. [20, 21] Reduced compliance in tions, comparing three different interventions. In a clinical practice setting may result in reduced contrast, Tosteson et al.
[24] compared costs and effectiveness of the drug, so models that evaluate the QALYs of two different interventions in patient population-based impact of a strategy in clinical populations with different life expectancy. practice may provide a more representative estimate by factoring in the reduced compliance in the analy-2.2 Target Decision Maker sis. [22] None of the studies evaluated cost effectiveness Finally, the articles were reviewed with respect to from a broader perspective than that of the health whether the authors commented that results would service sector. The target decision-making audience be relevant to address the same decision problem was only explicitly stated in three (16%) of the within the different jurisdictions.
included studies (table I) . Specifically, Coyle et al. [13] stated the decision maker to be "a Canadian
Results
provincial Ministry of Health", the Office of Technology Assessment (OTA) [17] stated that the report
Summary of Included Papers
was commissioned by the US Senate Special Committee on Ageing, and Visentin et al. [29] commented A total of 18 publications reporting economic that the evaluation was targeting the Italian Health evaluation models satisfied the inclusion criteria Service. (table I) . These included four Markov state transition models [17, [23] [24] [25] and four simple decision It was, however, possible to infer a target decitrees. [26] [27] [28] [29] Nine studies were cost-utility analyses. sion maker for many of the remaining studies. For Of the studies published in the 1980s, six were from example, Ankjaer-Jensen and Johnell [19] commented the US. Eight studies were from European countries, that the analysis was "carried out in a Danish conall of which were published in the 1990s. The stud-text"; and the study by Cheung and Wren [30] [30] Study was carried out vs no treatment 5-15 years' treatment and varying risk of death from in New South Wales, myocardial infarction Australia ORT: $A9500-$A17 500 in symptomatic women with intact uteri ORT: $A45 800 to ORT being dominated in asymptomatic women with intact uteri ORT: $A6510-$A1 020 000 in women after hysterectomy CRT: $A26 100-1 450 000 in asymptomatic women with intact uteri CRT: $A9820-34 700 in symptomatic women with intact uteri Coyle Explicit Explicit Calcitonin vs no therapy; Results expressed as cost per life-year gained et al. [13] The target decision [26] CRT vs no treatment; avoided, treatment vs no therapy etidronate vs no treatment CRT: £138-£680 Etidronate: £1880 Calcitonin: £9075-£25 013
Garton No Inferred HRT with screening vs Base-case results expressed as incremental cost per et al. [33] Bone mass measurement vs no universal treatment with HRT fracture prevented measurement (i.e. screening) without screening Universal treatment vs screening: £1710 Geelhoed Inferred Inferred ORT vs no treatment and Results expressed as incremental cost per QALY, et al. [23] Western [27] The UK NHS Screening vs no screening screening followed by HRT in Universal treatment for 10 years vs no treatment: £40 080 in followed by HRT high-risk patients vs no women with intact uteri, and £12 643 in hysterectomised treatment and universal women treatment with HRT vs no Screening followed by HRT treatment vs no treatment: treatment £34 971 in women with intact uteri and £17 169 in hysterectomised women [25] CRT for 15 years vs no CRT vs no treatment: $US32660 intervention (intact uterus) Visentin Yes Inferred Screening followed by calcitonin Results expressed as incremental cost per averted hip et al. [29] Italian Health Service vs screening, and universal fracture calcitonin treatment vs no Population-based approach: $US2 367 987 treatment Screening and treatment of high-risk patients $US838 120
Continued next page
Weinstein [34] No Inferred HRT vs no treatment in women Results expressed as incremental cost per QALY with and without osteoporosis CRT in women with uterus without osteoporosis: $US7420 and hysterectomy CRT in women with uterus with osteoporosis: $US5460 ORT in hysterectomised women without osteoporosis: $US4810 ORT in hysterectomised women with osteoporosis: $US3250
Weinstein No Yes ORT vs CRT (for 5 years) and Results expressed as incremental cost per QALY and Schiff [35] "… to synthesise the available CRT vs no treatment in women ORT vs CRT: >$US130 000 evidence in comparing the with intact uteri CRT vs no treatment: $US42 000 costs, risks and benefits of oestrogen-progestogen therapy and oestrogen-only therapy in post-menopausal women"
Weinstein
No Inferred ORT (for 5 years) vs no Results expressed as incremental cost per QALY and treatment and CRT vs ORT in ORT vs no treatment: $US72 100 Tosteson [37] women with intact uteri CRT vs ORT: CRT dominates ORT BMD = bone mineral density; BMI = body mass index; CRT = estrogen and progestogen therapy; DKK = Danish kroner; HRT = hormone replacement therapy (either ORT or CRT); ICER = incremental cost-effectiveness ratio; ORT = estrogen-only therapy; OTA = Office of Technology Assessment; $A = Australian dollars.
to target a decision-making body in New South unclear how this model estimated hip fracture risk Wales, Australia. Similarly, Daly et al. [31] and reduction as a consequence of treatment. Torgerson and Reid [27] appeared to tailor their analyThe main assumptions were clearly stated and ses to be applicable in a British context without justified in most studies. For example, Coyle et explicitly stating this. It was not possible to infer a al., [13] the OTA [17] and Tosteson and Weinstein [25] decision-making audience in eight studies.
clearly presented all assumptions in the model as well as any omissions. The study by Visentin et The research question was explicitly stated in al. [29] was not entirely transparent; for example, it seven studies (39%) [ A common feature of the models in this review and Reid [27] did not explicitly state a research queswas the use of epidemiological studies to estimate tion but compared the (average) cost effectiveness the relative hip fracture risk reduction in the treated of screening followed by hormone replacement therpopulations. Three models based the hip fracture apy (HRT) treatment versus no screening and unirisk reduction estimates on individual clinical trial versal treatment.
data, [26, 28, 36] whereas two models based the effect estimates for one of the therapies on meta-analyses
Transparency of Reporting
of several trials. [13, 19] Of these studies, only two [13, 26] provided information about the clinical characterisThe vast majority of the studies specified that the tics of the populations of the trials target population was women living in the commuThe remaining studies based the effect estimate nity, though one study specifically considered wo-primarily on observational studies. One of these men in nursing homes, [27] and the target country studies [17] provided details of patient characteristics could be inferred for all studies. The target popula-in the studies on which the effectiveness estimate tions were also indicated for all models. Sex, was based, and two further studies presented patient postmenopausal status or age >50 years were used in characteristics only in terms of age range. [24, 36] most studies to identify the study population. SusSince the majority of studies provided only limitceptibility to osteoporosis, either via previous frac-ed patient information, the scope for assessing the ture [13] or low bone mineral density, [28] were also applicability of the results to the target populationused as descriptive factors. Some models evaluated and indeed other populations -was limited. Only hysterectomised women separately from those with two studies failed to provide any basis for the asa uterus in situ. [23, 27, 31, 32, 35] Two studies restricted the sumption on clinical effect. [27, 30] In spite of the fact analysis to Caucasian women only [23, 26] because of that limited information was provided on the popuan underlying difference in baseline hip fracture risk lation sample, the majority of the studies provided between ethnic groups.
references to primary studies that are likely to have The model structure was described in most of the given a more comprehensive description of the relestudies through an outline of all clinical outcomes vant patient sample. Only one study adjusted the incorporated into the structure or, where relevant, risks measured in the trials to the target population health states and transitions. One study did not pre-for the modelling exercise. [36] In spite of this, most sent the structure adequately: [29] it was, for example, studies appeared to use the best available data rele-vant to the stated or inferred decision maker (table use was relevant to the decision maker in four studies. [26, 27, 29, 33] 
II).
Of the nine cost-utility studies that were included The studies were also reviewed to assess whether thors, either implicitly or explicitly, based utility they had considered the implications of variation in estimates on weights that were originally assumed input parameters using sensitivity analysis. A total by Weinstein. [34] For example, Weinstein [34] asof ten studies (55%) explored alternative assumpsumed that hip fracture would result in a loss of 0.05 tions of effect estimate in sensitivity analyses. quality-adjusted years per remaining year of life, Ankjaer-Jensen and Johnell [19] used 'best case' and and similar assumptions were made for menopausal 'worst case' scenarios in their analysis of effectivesymptoms and endometrial cancer. With the excepness, and Rosner et al. [36] explored the 95% CI tion of the three studies mentioned above which boundaries for vertebral fracture rates in the model. used sample-based utility weights, it was difficult to Similarly, Cheung and Wren [30] varied the risk of assess the relevance of the utilities assumed by death from myocardial infarction over a range, and Weinstein [34] to particular healthcare decision makthe OTA [17] varied the risk of all clinical parameters ers or jurisdictions (table II) .
(bone loss, cancer and heart attack) in its model. Daly et al. [31, 32] varied both the magnitude and the
Resource Use Data and Unit Costs
duration of effect estimates in their sensitivity analyThe sources of resource use were explicit for the sis, whereas Geelhoed et al. [23] explored the impact majority of the studies included in the review; only of HRT on different body systems (e.g. breast canthree studies omitted reporting this informa-cer) in the sensitivity analysis. The study by Coyle et tion. [25, 27, 29] For example, resource use estimates and al. [13] based its effect estimate on a meta-analysis of assumptions were explicit in the study reported by several trials and found that the cost-effectiveness Ankjaer-Jensen and Johnell, [19] and Rosner et al. [36] estimate was highly sensitive to the inclusion of one used a Delphi panel to estimate resource use. Some particular study. studies included drug costs only in the estimate of These sensitivity analyses were largely undertakresource use. [26] [27] [28] [29] Sixteen studies in the review re-en to explore parameter uncertainty (e.g. due to ported most sources of unit costs incorporated in the sampling uncertainty) rather than explicitly to conanalyses whereas the remaining two studies [27, 29] did sider possible variability in clinical effects within or not report any sources for unit cost data. between jurisdictions. In part, this comment also It was difficult, if not impossible, to judge wheth-applies to the two models which estimated hip fracer the estimates of resource use and unit costs were ture rates from BMD.
[24,37] However, varying the relevant to the decision maker for studies that did population baseline hip fracture risk in these studies not explicitly state the decision-making audience for (for example, baseline hip fracture risk was inthe study (table II) . For the studies for which a creased by 100% and decreased by 50% in the decision maker was explicit or could otherwise be Tosteson et al. [24] study) would have been of interest inferred, the sources of resource use were largely to decision makers, as adjustment of baseline risk is judged to be relevant. The target decision maker was often used to adapt the results of models between not clear in the studies by Tosteson et al. [24, 25] and geographical areas (for an example see adaptation of Weinstein; [34] however, the resource use would have the WOSCOPS [West Of Scotland COronary Prebeen relevant provided that the target decision mak-vention] study results to Belgium by Caro et al., [38] er was Medicare. It was not clear whether resource and the work by Palmer et al. [39] ).
Assumptions of compliance and duration of treat-across countries. Furthermore, none of the investiment were made without adjustment to clinical prac-gators attempted to use cost estimates applicable to a tice circumstances in the majority of studies in the broader audience of decision makers within or bereview. For example, the OTA [17] assumed 100% tween countries by using a range of costs or treatcompliance over 10, 20, 30 and 40 years; and Daly ment patterns representing geographical differences. et al. [32] assumed 100% compliance over 5, 10, 15 The sensitivity of the study results to national variaand 20 years. The eight studies that took compliance tion in cost per fracture was explored only in the into consideration differed in their definition of lack study reported by Coyle et al., [13] who found that of compliance, but often it meant simply that pa-their cost-effectiveness estimate was markedly retients 'declined to accept' therapy [30] or that patients duced when using cost calculations from an alterna-'accepted but discontinued' therapy [31] (table II) . tive cost-of-illness study. Generally, the cost-effectiveness estimates were 2.6 Authors' Comments on Generalisability found to be sensitive to the assumption of compliance, but the recommended policy decision of the Overall, four studies explicitly commented on the studies remained unchanged (table II) . For example, issue of the generalisability of their analysis to other Tosteson et al. [24] assumed 100% compliance over settings in their presentation or discussion of results 15 years in the base case model, but varied compli- (table IV) . [13, 19, 27, 35] For example, Coyle et al. [13] ance to 30% in the sensitivity analysis and found commented that the results were sensitive to the that cost-effectiveness estimates were sensitive to baseline population hip fracture risk, and for that the assumption of compliance. reason the generalisability of the results was unOne study [13] explored the sensitivity of health clear. state valuation on the results of the analysis. Alternative utilities that assigned a 0.1 higher utility 3. Discussion weight to the post-fracture health state for women This paper has reviewed the use of decisionreceiving nasal calcitonin were identified. The estianalytic cost-effectiveness models, in a specific mates of incremental cost-effectiveness ratio inclinical area, to assess a range of factors associated creased as a result of the alternative utilities. Again, with the potential relevance of an analysis to a however, this sensitivity analysis was associated particular decision maker, and the extent to which its more with parameter uncertainty than geographical results might be transferable to other jurisdictions. variation.
More general issues of good methods in decisionOnly five studies contrasted their findings with analytic cost-effectiveness modelling have been other economic evaluation studies in the area (table considered elsewhere, [40] [41] [42] and a general critical III). For example, the report by the OTA [17] provided review of cost-effectiveness models in osteoporosis a comprehensive discussion of methodology, costs, has also previously been published. [14] clinical assumptions and results in relation to other
We found that only three (16%) of the studies in cost-effectiveness analyses. In principle, this would this review provided explicit details of the jurisdichave allowed decision makers to assess whether tion and target decision maker, although it was other studies in the field had incorporated more possible to infer the decision context from other appropriate data inputs for their jurisdiction.
information provided in some studies. Similarly,
Resource Use and Unit Costs
authors frequently reported the methods and results Most studies applied unit cost data to the analysis of studies for which a firm research question has not relevant to the country for which the study was been stated. To aid decision making, models also targeted. Three studies used regional cost esti-need to be clear about the decision problem(s) being mates. [23, 30, 36] None of the models accommodated addressed. The majority of reports in the review differences in treatment patterns within regions or defined the study setting, patient population, model [19] mineral density screening. 'Compliance' of 100% approach under both assumptions of 'compliance' and 50% was explored (attendance)
Coyle et al. [13] Compliance was proportion of patients taking Analysis was sensitive to the assumption about compliance medication after 1 year. Base-case was 50% after with therapy. However, the overall results of the analysis did 1 year. The impact of 25% and 75% compliance not change was tested as well as 10% superior compliance with calcitonin Daly et al. [31] Compliance was % of patients continuously taking Incremental cost effectiveness increased ratio with reduced the drug. Compliance of 100% in first 5 years compliance over all treatment strategies. The overall results of falling to 50% (estrogen only) and 67% falling to the analysis did not change 33% (estrogen and progestogen) Garton et al. [33] Compliance rate used implied % patients initiating Universal hormone replacement therapy was more cost therapy and continuing beyond year 1 to complete effective than screening strategy, under both high and low a course of 10 years of treatment. Compliance of compliance. However, if screening could increase compliance 10%, 30% and 50% were explored then screening could prove more cost effective Geelhoed et al. [23] Assumed that patients who fill prescriptions but do Net cost per QALY would increase ('more than double') under not take the drug incur costs but gain no benefits. a scenario of reduced compliance Explored scenario where 70% of prescriptions are filled but only 30% are taken as directed Rosner et al. [36] Different rates of willingness of patients to initiate
The model was 'moderately sensitive' to changes in and continue treatment were incorporated in the willingness to initiate and willingness to continue. One model ranging from 18.1% to 100%. These were strategy was particularly sensitive but it remained cost based on epidemiological studies effective under the assumption that public willingness to pay for a QALY is more than $US100 000
Torgerson and Compliance rates were defined as 'willingness to The outcome of the evaluation was sensitive to the Reid [27] initiate' therapy. Once therapy initiated, 100% assumption of compliance. More than 50% need to initiate compliance assumed in 30 years. Different rates of therapy ('be compliant') in order for targeted intervention to be willingness of patients to initiate and continue cost effective treatment were varied from 18.1% to 100% and based on epidemiological studies Tosteson et al. [24] Assumed 100% compliance with treatment varied Results were 'sensitive', but compliance did not change the from 5-year to lifetime use (baseline model main conclusion of the model: screening remained more cost 15-year). Explored 30% compliance in sensitivity effective than universal treatment analysis structure and key assumptions in a transparent man-mates of clinical effectiveness are transferable bener.
tween countries in a way that resource use and cost data are not. Perhaps reflecting this assumption, the Once the target decision maker/jurisdiction and papers in the review generally made more effort to decision problem have been established, the former ensure (and to be seen to ensure) that their cost will need to decide whether the data inputs and inputs (at least unit costs) were specific to their assumptions in the model are the best available for target jurisdiction. Most studies were prepared to their context. The majority of the reports provided use clinical data from studies undertaken outside the sources for clinical and economic data, and their context of stated decision maker. As in other clinical valuation. The data inputs to those models for which areas, an exception to this assumption of the transa decision maker was stated or could be inferred ferability of clinical data is the adjustment of baseappeared to be relevant and, as far as could be line risks to make them specific to a particular judged from only the published article, these were jurisdiction (usually country) while assuming that the 'best available' for the decision context. There is often an implicit assumption in models that esti-the relative treatment effect is exchangeable geo- Table IV . Authors' comments on the generalisability of the results
Study
Did the authors explicitly address the issue of transferability of the results to other jurisdictions?
Ankjaer-Jensen and Yes. The authors commented that the results are limited to a Danish context, considering wide variability in Johnell [19] drug costs across countries. For example, they commented that drugs cost 50% less in Sweden and that this would influence the results Cheung and Wren [30] No Coyle et al. [13] Yes. The authors commented that the results are sensitive to baseline risks of fracture in the population and that the generalisability to other jurisdictions was, therefore, unclear Daly et al. [31] No Daly et al. [32] No Francis et al. [26] No Garton et al. [33] No Geelhoed et al. [23] No OTA [17] No
Rosner et al. [36] No
Torgerson and Reid [27] No
Torgerson and Kanis [28] Yes. The authors commented that the cost of hip fracture was excluded because the hospital length of stay varies between UK regions and therefore an estimate based on a region with long stay would not apply to an estimate in a region with short stay
Tosteson et al. [24] No. However, the authors acknowledged that baseline fracture risk in the population is important to the cost-effectiveness ratio Tosteson and Weinstein [25] No
Visentin et al. [29] No. However, the authors noted that the high cost-effectiveness ratio may have been due to a relatively low incidence of hip fracture in the Italian population compared with other populations
Weinstein [34] No
Weinstein and Schiff [35] Yes. The authors stated that the cost advantage of the estrogen-progestogen alternative would have been even greater if British recommendations on more frequent endometrial monitoring had been adopted Weinstein and Tosteson [37] No OTA = Office of Technology Assessment.
graphically. [38] This adjustment of baseline risks was are two aspects to this decision-maker preference. rarely undertaken in the sample of papers re-The first is the position a given decision maker takes viewed, [24] although the effect of variation in these on the most appropriate utility estimation methods parameters for the generalisability of analyses was (e.g. use of patient or public preferences). The secdiscussed in another paper. [13] ond is the issue of whether the preferences of individuals outside the particular jurisdiction of interest Little attempt was made to justify the particular are acceptable. utilities used with respect to the target decision maker. This may reflect the limited amount of utility One aspect of the review was to assess the extent data available relating to osteoporosis. In other to which studies had assessed, using sensitivity analwords, the authors often used any utility data that ysis, the impact of variability in parameter estimates were available -in the majority of studies this was associated with the jurisdiction. In principle, this the assumption (rather than empirical elicitation) sort of analysis might be undertaken for two reasons. made by Weinstein. [34] Increasingly, decision mak-First, there may be variability in clinical and/or cost ers will be specific about the type of health state parameters within a given jurisdiction. If there was utility data they wish to see in economic evaluations. good reason to think that this level of variability For example, NICE has indicated that it wishes to might affect the conclusions of the analysis, sensisee the use of public preferences relating to the tivity analysis would be imperative. Secondly, to British population in cost-utility analyses submitted assess, by appropriate variation in parameter values, to its technology assessment programme.
[42] There whether the results of the model as they apply to the
